09 — Stem cell exhaustion
"Integrative" hallmark in the classification of López-Otín et al., Cell 2023 (10.1016/j.cell.2022.11.001). It results largely from the accumulation of primary damage (01-05) and of the antagonistic responses (06-08).
1. Definition
With age, adult stem cells (blood, muscle, gut, skin, brain, bone) decline in number and above all in quality. They renew themselves less well, differentiate incorrectly or stay stuck in dormancy. The tissue then repairs its cell losses more slowly and less well.
In plain terms: stem cells are the body's "spare parts reserve". Over the years, the stock runs down and the parts supplied are of lower quality.
2. Mechanisms and sources
Intrinsic causes (inside the stem cell)
- DNA damage and mutations: haematopoietic stem cells (HSCs, the source of blood cells) accumulate mutations. Some give a growth advantage: this is clonal haematopoiesis (CHIP), detailed in 11 (Jaiswal 2014, 10.1056/NEJMoa1408617; Steensma 2015, 10.1182/blood-2015-03-631747).
- Epigenetic drift: the chemical marks that tell the cell which genes to read become blurred. A loss of epigenetic information is enough to accelerate aging traits in mice, and it is partly reversible (Yang 2023, 10.1016/j.cell.2022.12.027).
- Loss of polarity: in old HSCs, increased activity of the protein Cdc42 disorganises the cell; inhibiting it pharmacologically rejuvenates their function in mice (Florian 2012, 10.1016/j.stem.2012.04.007).
- Quiescence tipping into senescence: the satellite cells of muscle (muscle stem cells) of very old mice lose their reversible dormancy and enter senescence via p16^INK4a; repressing p16 restores their regenerative capacity (Sousa-Victor 2014, 10.1038/nature13013).
- Differentiation bias: old HSCs produce more myeloid (inflammatory) cells and fewer lymphocytes, which contributes to immunosenescence.
Extrinsic causes (the niche and the blood)
- Deteriorated niche: the immediate environment of the stem cell sends bad signals. In the gut, mTORC1 signalling in Paneth cells links stem cell function to calorie intake (Yilmaz 2012, 10.1038/nature11163).
- Old systemic environment: exposing old stem cells to young blood (heterochronic parabiosis) partly restores their activity, and old blood inhibits it (Conboy 2005, 10.1038/nature03260; see 10).
- Neighbouring senescent cells: their inflammatory secretion (SASP) impairs stem cells; eliminating senescent cells with ABT263 (navitoclax) rejuvenates HSCs in mice (Chang 2015, 10.1038/nm.4010).
3. Symptoms and clinical manifestations
- Blood and immunity: anaemia in older people, weaker vaccine response, myeloid bias. CHIP is present in more than 10 % of people over 70, associated with a higher risk of blood cancer, overall mortality and cardiovascular disease (Jaiswal 2014; Jaiswal 2017, 10.1056/NEJMoa1701719).
- Muscle: slower regeneration, contribution to sarcopenia (loss of mass and strength) and frailty.
- Brain: decline in hippocampal neurogenesis, linked in mice to cognitive decline (Villeda 2011, 10.1038/nature10357).
- Skin, hair, gut, bone: slow wound healing, greying hair, slower gut repair, osteoporosis (imbalance of mesenchymal stem cells in favour of fat cells).
- Human evidence: mostly correlational (biopsies, blood sequencing). Causal evidence comes almost entirely from mice.
4. Interactions with the other hallmarks
- Genomic instability (01) and telomere attrition (02): main sources of intrinsic damage to stem cells; mutations are the engine of CHIP.
- Epigenetic alterations (03): at the heart of the loss of stem cell identity; direct target of partial reprogramming.
- Loss of proteostasis (04) and disabled macroautophagy (05): autophagy protects stem cell quiescence; its decline pushes towards senescence.
- Deregulated nutrient sensing (06): mTOR and IGF-1 set the balance between quiescence and activation (Yilmaz 2012).
- Mitochondrial dysfunction (07): the quality of mitochondria determines self-renewal capacity.
- Cellular senescence (08): terminal fate of exhausted stem cells, and a source of toxic signals for the niche (Sousa-Victor 2014; Chang 2015).
- Altered intercellular communication (10): old blood and an old niche inhibit stem cells (parabiosis).
- Chronic inflammation (11): CHIP amplifies inflammation, and inflammation in turn favours clonal expansion.
- Dysbiosis (12): the microbiota modulates the renewal of intestinal stem cells (link mostly preclinical).
5. Existing or investigational remedies
Partial reprogramming (box)
In 2006, Takahashi and Yamanaka showed that four factors (Oct4, Sox2, Klf4, c-Myc, called OSKM) take an adult cell back to the state of a pluripotent stem cell (iPS) (Takahashi 2006, 10.1016/j.cell.2006.07.024). Reprogramming cells from centenarians erases several marks of aging in vitro (Lapasset 2011, 10.1101/gad.173922.111).
The idea of partial reprogramming: apply these factors just enough to reset the epigenetic clock, without erasing the cell's identity.
- Risk: continuous OSKM expression in mice causes teratomas (tumours) (Abad 2013, 10.1038/nature12586).
- Cyclic: intermittent induction in progeroid mice improves aging traits and extends their life (Ocampo 2016, 10.1016/j.cell.2016.11.052).
- Without c-Myc (OSK): in the mouse eye, OSK restores vision after optic nerve injury and in old animals, in a way that depends on DNA demethylation (Lu 2020, 10.1038/s41586-020-2975-4).
- Normal old mice: long-term partial reprogramming changes molecular markers of aging with no tumour detected in the study (Browder 2022, 10.1038/s43587-022-00183-2).
- Human cells: transient reprogramming "up to the maturation phase" rejuvenates human fibroblasts by about 30 years on epigenetic and transcriptomic clocks (Gill 2022, 10.7554/eLife.71624).
- Chemical: human cells have been reprogrammed into iPS cells with small molecules alone (Guan 2022, 10.1038/s41586-022-04593-5), opening the way to non-genetic approaches.
In plain terms: it is like resetting a computer's settings without deleting the files. The danger is going too far and getting a cell that no longer knows what it is, or even becomes a tumour.
Table of interventions
| Intervention | Target | Level of evidence | Key result | Source |
|---|---|---|---|---|
| Cyclic partial OSKM reprogramming | Epigenome | Preclinical (progeroid mice) | Improved aging traits, extended life | Ocampo 2016 |
| OSK via viral vector (eye) | Epigenome, retinal neurons | Preclinical (mice) | Vision restored after injury and in old animals | Lu 2020 |
| Long-term partial reprogramming | Multi-tissue epigenome | Preclinical (wild-type mice) | Rejuvenated molecular markers, no tumour reported | Browder 2022 |
| Transient reprogramming in vitro | Human fibroblasts | Preclinical (human cells) | ~30 years of epigenetic rejuvenation | Gill 2022 |
| Senolytic ABT263 (navitoclax) | Senescent cells of the bone marrow | Preclinical (mice) | Old HSCs rejuvenated | Chang 2015 |
| Cdc42 inhibitor (CASIN) | HSC polarity | Preclinical (mice) | Function of old HSCs restored | Florian 2012 |
| Repression of p16^INK4a | Muscle stem cells | Preclinical (mice) | Muscle regeneration restored | Sousa-Victor 2014 |
| Caloric restriction / mTORC1 inhibition | Intestinal niche | Preclinical (mice) | Increased intestinal stem cell function | Yilmaz 2012 |
| Parabiosis / young blood factors | Systemic environment | Preclinical (mice) | Activity of muscle and liver stem cells restored | Conboy 2005 |
| Infusion of allogeneic mesenchymal stem cells | Frailty | Human phase I/II trial | Acceptable safety, signs of functional improvement (small sample) | Golpanian 2017 |
No intervention specifically targeting stem cell exhaustion is approved for aging. HSC transplants are approved, but for blood diseases, not for aging.
6. Open questions
- Safety of reprogramming in humans: how to avoid teratomas and loss of identity over years? What dose, which tissues, what delivery method?
- Causality: is stem cell exhaustion a cause or a consequence of tissue aging? The intrinsic vs niche share remains poorly quantified in humans.
- Measurement: simple biomarkers of stem cell "health" in humans are missing (apart from CHIP sequencing).
- Cancer dilemma: stimulating stem cells can favour mutated clones (CHIP, cancers). How to rejuvenate without selecting the bad clones?
- Heterogeneity: do results in mice (often progeroid) carry over to slowly renewing human tissues?
7. References
- López-Otín C. et al. (2023) Hallmarks of aging: An expanding universe. Cell. 10.1016/j.cell.2022.11.001
- Takahashi K., Yamanaka S. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 10.1016/j.cell.2006.07.024
- Lapasset L. et al. (2011) Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes Dev. 10.1101/gad.173922.111
- Abad M. et al. (2013) Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature. 10.1038/nature12586
- Ocampo A. et al. (2016) In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell. 10.1016/j.cell.2016.11.052
- Lu Y. et al. (2020) Reprogramming to recover youthful epigenetic information and restore vision. Nature. 10.1038/s41586-020-2975-4
- Browder K.C. et al. (2022) In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice. Nature Aging. 10.1038/s43587-022-00183-2
- Gill D. et al. (2022) Multi-omic rejuvenation of human cells by maturation phase transient reprogramming. eLife. 10.7554/eLife.71624
- Guan J. et al. (2022) Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature. 10.1038/s41586-022-04593-5
- Yang J.-H. et al. (2023) Loss of epigenetic information as a cause of mammalian aging. Cell. 10.1016/j.cell.2022.12.027
- Conboy I.M. et al. (2005) Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature. 10.1038/nature03260
- Villeda S.A. et al. (2011) The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 10.1038/nature10357
- Sousa-Victor P. et al. (2014) Geriatric muscle stem cells switch reversible quiescence into senescence. Nature. 10.1038/nature13013
- Yilmaz Ö.H. et al. (2012) mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature. 10.1038/nature11163
- Florian M.C. et al. (2012) Cdc42 activity regulates hematopoietic stem cell aging and rejuvenation. Cell Stem Cell. 10.1016/j.stem.2012.04.007
- Chang J. et al. (2015) Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nature Medicine. 10.1038/nm.4010
- Jaiswal S. et al. (2014) Age-related clonal hematopoiesis associated with adverse outcomes. NEJM. 10.1056/NEJMoa1408617
- Jaiswal S. et al. (2017) Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. NEJM. 10.1056/NEJMoa1701719
- Steensma D.P. et al. (2015) Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 10.1182/blood-2015-03-631747
- Golpanian S. et al. (2017) Allogeneic human mesenchymal stem cell infusions for aging frailty. J Gerontol A. 10.1093/gerona/glx056